Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid

Phase 2 Completed 42 enrolled Grifols, S.A. Grifols Biologicals, LLC · collab

RandomizedSingle-groupQuadruple-blindTreatment

Summary

The purpose of this study was to evaluate the efficacy and safety of plasma exchange with 5% albumin in beta-amyloid peptide clearance in cerebrospinal fluid, and its effects in patients with mild-moderate Alzheimer's disease.

Timeline

Start: 2007-07
Primary completion: 2011-02
Completion: 2011-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Albumin	Protein / enzyme biologic	5 %	—

Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid

Summary

Timeline

Drugs

Indications